NanoViricides, Inc. (NYSE: NNVC) Starts Presentation at the 2017 Marcum Microcap Conference
NanoViricides (NYSE: NNVC) is a development-stage company with a unique nanomedicine technology. The company is developing nanotechnology-based biomimetic anti-viral medicines, that it calls "nanoviricides®." Virus-specific nanoviricide drug candidates against five commercially important viral diseases, viz. seasonal and potentially-epidemic influenzas and bird flu, HIV/AIDS, cold sores and genital herpes infection, viral eye diseases, as well as dengue viruses, have demonstrated very high levels of effectiveness. For more information, visit the company's website at www.nanoviricides.com About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides to users (1) access to our news aggregation and syndication servers, (2) enhanced press release services, and…







